DJIA 17,798.49 -14.90 -0.08%
NASDAQ 5,127.53 11.38 0.22%
S&P 500 2,090.11 1.24 0.06%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

company name or ticker

Is Sarepta Therapeutics Worth the Risk?

Can Sarepta's highflying ways continue, or is it time to take profits?

PTC Therapeutics Presents Phase III Data on Translarna

Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update

Sarepta Down, Eteplirsen Likely to Face FDA Panel in Jan

BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta?

Jim Cramer's Top Takeaways: Helen of Troy, BioMarin, Energy Transfer Partners

Why Shares of Sarepta Therapeutics Inc Are Falling Today

A capital raise disappoints investors, sending shares lower.

Sarepta Therapeutics (SRPT) Stock Falls After Pricing Secondary Offering

Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop

Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?

Which of these two companies will win the race to successfully develop the first Duchenne muscular dystrophy treatment? Our team of contributors weigh in.
See More Articles...